Spirometrix, a US-based developer of breathing analysis technology, has raised $8.6m from a series B financing round led by its biosensor manufacturing partner, NGK Spark Plug.
Japan-based NGK, which invested $5m as a strategic partner, participated in the round alongside Simul Investments.
Founded in 2011, Spirometrix focuses on the research, development and commercialisation of novel breath analysis devices for application in disease diagnosis and management for asthma.
Dean Zikria, chief executive of Spirometrix, said: “This is a significant step in our strategy of creating a unique offering in the asthma space that includes sensors as well as a digital ecosystem allowing for insights leading to better clinical decision support.”
This latest round brings the total raised by the company to $12m, MobiHealthNews has reported. Following the round a member of NGK will join the board of directors of Spirometrix.